Within this latter drug class, saxagliptin and vildagliptin showed a significant reductions of depression-like symptom frequencies in patients with depression and diabetes, in all analyses we carried out in the FAERS (i.e., values from all disproportionality scores are significant) (see Table 4), adding preliminary and encouraging evidence (but less promising than those reported for GLP-1 analogues) to the very limited existing body of knowledge on the potential use of DPP-4 Inhibitors as an adjuvant in the treatment of depression. Here, GLP1R is linked to depressive disorder.